Type 2 diabetes and cardiovascular disease: Getting to the fat of the matter

Kerry B. Goralski, Christopher J. Sinal

Research output: Contribution to journalReview articlepeer-review

58 Citations (Scopus)

Abstract

The increasing national prevalence of obesity is a major public health concern and a substantial burden on the health care resources of Canada. In addition to the direct health impact of obesity, this condition is a well-established risk factor for the development of various prevalent comorbidities including type 2 diabetes, hypertension, and cardiovascular disease. Historically, adipose tissue has been regarded primarily as an organ for energy storage. However, the discovery of leptin in the mid 1990's revolutionized our understanding of this tissue and has focused attention on the endocrine function of adipose tissue as a source of secreted bioactive peptides. These compounds, collectively termed adipokines, regulate a number of biological functions including appetite and energy balance, insulin sensitivity, lipid metabolism, blood pressure, and inflammation. The physiological importance of adipokines has led to the hypothesis that changes in the synthesis and secretion of these compounds in the obese are a causative factor contributing to the development of obesity and obesity-related diseases in these individuals. Following from this it has been proposed that pharmacologic manipulation of adipokine levels may provide novel effective therapeutic strategies to treat and prevent obesity, type 2 diabetes, and cardiovascular disease.

Original languageEnglish
Pages (from-to)113-132
Number of pages20
JournalCanadian Journal of Physiology and Pharmacology
Volume85
Issue number1
DOIs
Publication statusPublished - Jan 2007

ASJC Scopus Subject Areas

  • Physiology
  • Pharmacology
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Type 2 diabetes and cardiovascular disease: Getting to the fat of the matter'. Together they form a unique fingerprint.

Cite this